Statin therapy to reduce the risk of recurrent pancreatitis
Ended Awarded Last action
- Contract number
- HHSN26100007
- Awardee
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $437,054
Award facts
- Contract value 39% obligated
-
- $437,054.38 Current, with exercised options
- $1,114,905.38 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Evanston, IL 60208, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$233,670 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $245,426 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $425,298 |
About this award
This federal contract award, with an ID of HHSN261201200035I|HHSN26100007, was made by the National Cancer Institute (NCI) to Northwestern University to conduct a clinical trial studying the effects of simvastatin on reducing the risk of recurrent pancreatitis. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early-phase clinical research. The $1,114,905.38 contract does not have a set-aside designation.
The clinical trial will randomize 30 patients diagnosed with recurrent pancreatitis to receive either simvastatin or a placebo, with the goal of having 24 complete the 6-month follow-up. Northwestern University is serving as the prime contractor, with Cedars-Sinai Medical Center, Kaiser Permanente Los Angeles Medical Center, and the University of Pittsburgh as subcontractors. This contract supports NCI's efforts to develop new cancer prevention agents and advance scientific understanding of the underlying mechanisms of disease.
Quick answers
Who was awarded contract HHSN26100007?
HHSN26100007 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 17, 2015.
How much is contract HHSN26100007 worth?
The government has obligated $437,054 on HHSN26100007. Its potential value, with all options, is $1,114,905.
Is contract HHSN26100007 an order under another contract?
Yes. HHSN26100007 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100007 competed?
The extent of competition for HHSN26100007 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award